AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02980653
Drug: Megestrol acetate (MA) 400 mg/day
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
Trial: NCT00069745
Drug: Satraplatin
RxNorm normalized name: Satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00069745
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01449487
Drug: PPC-5650
RxNorm normalized name: GLYCERIN 2 g in 100 mL TOPICAL CREAM [Absolute PPC]
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
Trial: NCT02173951
Drug: Deferiprone
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat \> 90 % and or LPI \> 0.6 will start deferiprone 75 mg/kg/d
Trial: NCT02068599
Drug: TV-45070
RxNorm normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Trial: NCT02959606
Drug: Sarpogrelate SR 300mg
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02959606
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00291915
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01106950
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
Trial: NCT01106950
Drug: Denileukin diftitox
RxNorm normalized name: Denileukin diftitox
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 ug/kg/day will be administered on day -1 and day -2 intravenously.
Trial: NCT01106950
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
Trial: NCT04799873
Drug: AAT( Alpha 1 Antitrypsin)
RxNorm normalized name: ARO-AAT
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAT administration based on clinical indication
Trial: NCT00680173
Drug: pegylated interferon alpha 2a and plus ribavirin
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Trial: NCT00448149
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
Trial: NCT01428128
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
Trial: NCT00118287
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC or IV
Trial: NCT03478995
Drug: GX-I7
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GX-I7 25mg/ml/vial
Trial: NCT03402087
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00762177
Drug: Fluoride
RxNorm normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice a day for 14 days
Trial: NCT00762177
Drug: Fluoride, Triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice daily for 14 days
Trial: NCT00762177
Drug: Stannous Fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brush twice daily for 14 days
Trial: NCT03923842
Drug: Denosumab Inj 120 MG/1.7ML
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
Trial: NCT00541775
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
Trial: NCT00541775
Drug: Comparator: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
Trial: NCT00541775
Drug: Comparator: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \>= 1500 mg.
Trial: NCT00032487
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
Trial: NCT00032487
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
Trial: NCT00032487
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
Trial: NCT00032487
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
Trial: NCT00513630
Drug: Glipizide
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00513630
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02478502
Drug: cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
Trial: NCT04518410
Drug: SNG001
RxNorm normalized name: SNG001
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Camostat
RxNorm normalized name: camostat
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: CASIRIVIMAB + IMDEVIMAB
RxNorm normalized name: casirivimab / imdevimab
DrugBank: Imdevimab (DB15940)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for Bamlanivimab 7000mg
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for Bamlanivimab 700mg
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for Camostat
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Trial: NCT03357393
Drug: Propofol-Lipuro
RxNorm normalized name: PROPOFOL-LIPURO
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol is given as sedation to both intervention arms.
Trial: NCT04518410
Drug: Placebo for SAB-185 (low dose)
RxNorm normalized name: SAB-185
DrugBank: SAB-185 (DB16491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for BMS-986414 + BMS-986413
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for AZD7442 (IV)
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for AZD7442 (IM)
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Trial: NCT04518410
Drug: Placebo for SAB-185 (high dose)
RxNorm normalized name: SAB-185
DrugBank: SAB-185 (DB16491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Trial: NCT00656812
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 on day 1 of a 21-day treatment cycle
Trial: NCT00656812
Drug: 2-CdA
RxNorm normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
Trial: NCT02478788
Drug: mixed amphetamine salts-extended release (MAS-XR)
RxNorm normalized name: Amphetamine Mixed Salts Extended-Release Capsules
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
Trial: NCT00901498
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
Trial: NCT00901498
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
Trial: NCT00901498
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
Trial: NCT00901498
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
Trial: NCT00901498
Drug: BMS-708163
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
Trial: NCT02084342
Drug: tranexamic acid and sodium chloride injection
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
Trial: NCT02084342
Drug: desmopressin acetate injection
RxNorm normalized name: Desmopressin Acetate Injection
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
Trial: NCT00689143
Drug: sargramostim
RxNorm normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02602197
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
Trial: NCT02602197
Drug: Dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
Trial: NCT00669344
Drug: Exelon (rivastigmine)
RxNorm normalized name: rivastigmine Oral Capsule [Exelon]
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
Trial: NCT01221909
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
Trial: NCT01221909
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5cc saline solution
Trial: NCT00002874
Drug: bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
Trial: NCT03509584
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administration of nivolumab
Trial: NCT03509584
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administration of ipilimumab
Trial: NCT01384409
Drug: KW-3357
RxNorm normalized name: Antithrombin (human variant kw-3357)
DrugBank: Antithrombin Alfa (DB11166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion once a day
Trial: NCT00136474
Drug: Amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given 30-60 minutes prior to daily radiation therapy
Trial: NCT00001931
Drug: N-0923
RxNorm normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00839826
Drug: Rivaroxaban (BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
Trial: NCT00839826
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg bid
Trial: NCT04113993
Drug: Bazedoxifene Acetate
RxNorm normalized name: Bazedoxifene Acetate
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
Trial: NCT01197066
Drug: Certolizumab Pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab Pegol 200mg
Trial: NCT01980888
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg tablet administered orally twice daily
Trial: NCT01980888
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
Trial: NCT01980888
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
Trial: NCT00303797
Drug: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00303797
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03122665
Drug: Nefopam Low dose
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion at 0.5 mg/ml for three hours.
Trial: NCT03122665
Drug: Nefopam High dose
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion at 1.0 mg/ml for three hours.
Trial: NCT02416141
Drug: fast release oro dispersible tramadol 50 mg
RxNorm normalized name: Oro Clense
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: idem arm 1
Trial: NCT00062504
Drug: Talampanel
RxNorm normalized name: Talampanel
DrugBank: Talampanel (DB04982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
Trial: NCT04267042
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide is a corticosteroid that is commonly used intranasally to treat CRS.
Trial: NCT03357393
Drug: morphine-scopolamine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as premedication for the Control arm and one of the interventions arms.
Trial: NCT04441398
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
Trial: NCT03679884
Drug: Daridorexant 10 mg
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant 10 mg film-coated tablets
Trial: NCT03679884
Drug: Daridorexant 25 mg
RxNorm normalized name: daridorexant 25 MG
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant 25 mg film-coated tablets
Trial: NCT03679884
Drug: Daridorexant 50 mg
RxNorm normalized name: daridorexant 50 MG
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daridorexant 50 mg film-coated tablets
Trial: NCT00665639
Drug: micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00665639
Drug: caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02969304
Drug: dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate
Trial: NCT03357393
Drug: Glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as premedication for one of the intervention arms..
Trial: NCT00494156
Drug: aspirin and clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no